Nasdaq ardx.
Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...
Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock. Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 3, 4:15PM CDT . Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney diseases. These include irritable bowel syndrome, chronic ...730% upside stock according to Citigroup Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the …ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58.Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Sep 20, 2021 6:14AM EDT. Every investor in Ardelyx, Inc. (NASDAQ:ARDX) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we ...
The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ...
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...
Ardelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …NasdaqGM:ARDX Insider Trading Volume June 12th 2021 Ardelyx is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.Mar 6, 2023 · On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ... WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .View Ardelyx, Inc ARDX investment & stock information. Get the latest Ardelyx, Inc ARDX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 ...Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.Ardelyx, Inc. (NASDAQ: ARDX): $3.63 per Share. Ardelyx is a biopharmaceutical company focused on developing and commercializing drug candidates that address significant unmet medical needs. Its current product takes a novel approach to treating irritable bowel syndrome. Pipeline products include a small-molecule therapy for …
The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ...Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.
Dec 18, 2022 · Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ... Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. Here's what investors need to know. Shares of Ardelyx ( ARDX 7.44%) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. Ardelyx's ...Ardelyx (ARDX) Ardelyx (NASDAQ: ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs. The stock ...Ardelyx Stock Price, News & Analysis (NASDAQ:ARDX) $4.37 +0.28 (+6.85%) (As of 11/29/2023 ET) Compare Today's Range $4.11 $4.40 50-Day Range $3.29 $4.38 52 …The US FDA has accepted an NDA resubmission from Ardelyx ( NASDAQ: ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. The agency determined the application is subject a a class 2 ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ...
Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.
Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ...Ardelyx, Inc. Common Stock (ARDX) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ARDX Edit my quotes Ardelyx, Inc. Common Stock (ARDX) 0 Add to Watchlist Add to Portfolio Quotes...Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...WALTHAM, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...26 thg 6, 2020 ... Buy NASDAQ Composite Components: Price-Forecasting Models for Ardelyx, Inc. ARDX Stock (Series #771) (Paperback) at Walmart.com.Ardelyx (ARDX) Ardelyx (NASDAQ: ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs. The stock ...Ardelyx, Inc. (NASDAQ:ARDX) Number of Hedge Fund Holders: 16 Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney ...Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.Force Index charts of Daily price volume action, Weekly price volume action, Monthly price volume action of Ardelyx, Inc. ARDX NASDAQ. Data to use: Daily ...Shares of Ardelyx, Inc. (NASDAQ:ARDX) got a boost, shooting 37% to $1.6750 after the company announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for ...Instagram:https://instagram. nyse prudentialdell earnings releasebest dividend aristocratsp and g dividend The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ...Ardelyx Inc (NASDAQ:ARDX) is the most popular stock in this table. On the other hand Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS ) is the least popular one with only 8 bullish hedge fund positions. eastwest bank in philippinesbest dental insurance 2023 Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ... best cryptocurrency portfolio tracker Nov 24, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days. Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...